Metabolic domino: New concept in lifestyle medicine

Drugs of Today

Volumn 42, Issue SUPPL. C, 2006, Pages 9-16

  Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CATHEPSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HANDLE RENIN PEPTIDE; HYDRALAZINE; LOSARTAN; NICARDIPINE; PIOGLITAZONE; PLACEBO; PRORENIN RECEPTOR BLOCKER; RAMIPRIL; RAS PROTEIN; UNCLASSIFIED DRUG; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; GENETIC PREDISPOSITION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 33846406957     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Itoh, H. What is 'metabolic domino effect'?-new concept in lifestyle-related diseases. Nihon Rinsho 2003, 61: 1837-43 (in Japanese).
2. Viberti, G., Wheeldon, N.M. for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-8, 2002.
3. Luetscher, J.A., Kraemer, F.B., Wilson, D.M., Schwartz, H.C., Bryer-Ash, M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl Med 1985, 312: 1414-7.
4. Nguyen, G., Delarue, F., Burckle, C., Bouzhir, L., Giller, T., Sraer, J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109: 1417-27.
5. Ichihara, A., Hayashi, M., Kaneshiro, Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004, 114(8): 1128-35.
6. Hansson, L., Lindholm, L.H., Niskanen, L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-6.
7. Yusuf, S., Gerstein, H., Hoogwerf, B. et al. for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001, 286: 1882-5.
8. Dahlof, B., Devereux, R.B., Kjeldsen, S.E. et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359: 995-1003.
9. Lithell, H., Hansson, L., Skoog, I. et al. for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21: 875-6.
10. Granger, C.B., McMurray, J.J., Yusuf, S. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003, 362: 772-6.
11. Julius, S., Kjeldsen, S.E., Weber, M. et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004, 363: 2022-31.
12. Nakaya, H., Sasamura, H., Hayashi, M., Saruta, T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001, 12: 659-66.
13. Ishiguro K., Sasamura H. et al. Developmental activity of the renin-aldosterone system during the 'critical period' modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 2007 (in press).
14. Julius, S., Nesbitt, S.D., Egan, B.M. et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354: 1685-97.
15. Tanaka, T., Fukunaga, Y., Itoh, H. et al. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 2005, 508: 255-65.
16. Dormandy, J.A., Charbonnel, B., Eckland, D.J. et al. for the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005, 366; 1279-89.